Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C. Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2
Requena G, Ma L, Sturmer T, Layton JB, DiBello J. Association between an acute, drug-induced decrease in high-density lipoprotein cholesterol levels and risk of cardiovascular events. Clin Drug Invest. 2020 Aug;40:747-54. doi: 10.1007/s40261-020-00935-1
Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Hur P. Evaluation of the feasibility of a web-based survey to assess patient-reported symptom improvement and treatment satisfaction among patients with psoriatic arthritis receiving Secukinumab. Clin Drug Invest. 2019 Dec;39(12):1205-12. doi: 10.1007/s40261-019-00856-8
Wilson MR, Gutierrez B, Offord S, Blanchette CM, Eramo A, Earnshaw SR, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs Context. 2016 Mar 11;5:212273. doi: 10.7573/dic.212273
Sasane R, Mitra D, Hodgkins P, Davis KL. Childhood ADHD in Europe: a comparison of patient and physician profiles across countries. Poster presented at the 23rd ECNP Congress; August 2010. [abstract] Eur Neuropsychopharmacol. 2010 Aug; 20(Suppl. 3):S616-7.
Mitra D, Sasane R, Hodgkins P, Davis KL. Management of ADHD among children in Europe: a comparison of practice patterns across countries. Poster presented at the 23rd ECNP Congress; August 2010. [abstract] Eur Neuropsychopharmacol. 2010 Aug; 20(Suppl. 3):S625-6.
Williams VSL, Fehnel SE, Hollis KA, Hogue SL. Antidepressant induced sexual dysfunction in Europe: a preliminary investigation. Eur Neuropsychopharmacol. 2004 Jan 1;14:S180.
McKenna SP, Doward LC, Davey KM. The development and psychometric properties of the MSQOL: a migraine-specific quality-of-life instrument. Clin Drug Invest. 1998;15(5):413-23.